MIAMI--(BUSINESS WIRE)--Bio-Tissue™, Inc., the industry leader in regenerative tissue therapies for ocular surface diseases and disorders, today announced it has attained 33 percent unit growth and a 7-year compounded annual growth rate (CAGR) of 35 percent. With nearly 200,000 units shipped across all product lines since 2006 and more than 150,000 successful human transplantations, Bio-Tissue’s products are used by eye care professionals worldwide to manage ocular surface diseases and conditions.
Help employers find you! Check out all the jobs and post your resume.